News | May 05, 2009

Breast Surgeons Meeting Discusses Laser Treatment for Benign Breast Tumors

May 5, 2009 - A panel at the recent meeting of the 10th Annual Meeting of the American Society of Breast Surgeons, held April 22-26 in San Diego, included discussion of the advantages of a new laser treatment for fibroadenomas, using the Novilase Breast Therapy to offer a minimally invasive alternative to lumpectomy.

Novilase Breast Therapy uses direct laser therapy to treat fibroadenomas. The system aims to treat these noncancerous tumors while minimizing risks and maintaining the breast’s natural shape and feel.

Among the panelists was Kambiz Dowlat, M.D., a professor of surgery at the Rush University Medical Center in Chicago. Dr. Dowlat pioneered laser treatment of small breast tumors. The procedure he developed is now performed with the Novilase Interstitial Laser Therapy device.

“With the X-ray guided laser technology we have today, lumpectomy is overkill,” said Dr. Dowlat. “Lumpectomy creates a significant scar and can deform the breast when you take the tumor out. Fibroadenomas can be precisely ablated with a laser, giving a superior result and less medical risk than lumpectomy. This is a great boon for patients because they can have their benign tumors treated without significant consequences for their health or appearance.”
Dr. Dowlat noted that breast health is moving toward treatments, such as Novilase, that are less invasive and have fewer side effects.
Tumors are now being detected at earlier stages when they are smaller. Because laser therapy is less intimidating for most women, the procedure provides them with a third treatment option besides surgery and a “watch and wait” approach, which may encourage them to take advantage of early detection.

Dr. Dowlat’s remarks emphasized several benefits of laser treatment over lumpectomy surgery, the traditional approach to treating fibroadenomas:
- Minimal scarring. Because no incision is made, laser treatment generally leaves only minimal scars.
- Natural shape and feel maintained. There is typically no “dimpling” with laser treatment because unlike a lumpectomy, the procedure does not remove tissue. In addition, the body’s natural healing process repairs the tumor site and restores the breast’s natural feel.
• Less risk of adverse reaction. Laser treatment can be performed using local anesthetic. A lumpectomy often requires IV sedation or a general anesthetic, which can be riskier.
• Less infection risk. The procedure involves the insertion of a laser probe and a thermal probe through two 1/8- inch skin nicks. The small size of the nicks keeps the infection risk extremely low. In contrast, a lumpectomy uses a 2 inch-to-3 inch incision, which creates a greater risk of infection.
• Faster recovery. A patient can resume normal activity within a few hours of the procedure. Recovery from a lumpectomy can take several days.
About 10 percent of all women will experience fibroadenomas during their lifetime. Although not cancerous, fibroadenomas can cause physical discomfort and also anxiety because of the association of lumps with breast cancer. Thus, after consultation with their physicians, many women with this condition request that their fibroadenomas be removed.

While Novilase uses direct laser therapy to treat fibroadenomas, laser ablation has been successfully used to treat benign prostate tumors. Novilase also uses the same image guidance for breast biopsy.

For more information:

Related Content

SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
RaySearch Releases New Version of RayCare OIS
Technology | Oncology Information Management Systems (OIMS) | July 13, 2018
RaySearch has released RayCare 2A, the latest version of its flagship oncology information system (OIS). RayCare is...
Breast Cancer Follow-up Imaging Varies Widely
News | Breast Imaging | July 13, 2018
July 13, 2018 — Follow-up imaging for women...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Invision Diagnostics Installs VolparaEnterprise Software to Enhance Mammography Image Quality
News | Mammography | July 11, 2018
Invision Diagnostics, a provider of mobile mammography services across North and South Carolina, announced that it is...
Breast Cancer Studies Ignore Race, Socioeconomic Factors
News | Women's Health | July 11, 2018
A new commentary appearing in the July issue of Cancer Causes & Control points to evidence that social factors help...
Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy
News | Radiation Therapy | July 11, 2018
Canadian nuclear power company Bruce Power and German-based Isotope Technologies Garching (ITG) signed an agreement to...
MedStar Georgetown University Hospital Now Clinical With RayStation and Hyperscan
News | Treatment Planning | July 05, 2018
MedStar Georgetown University Hospital in Washington D.C., has begun patient treatments using the RayStation treatment...
Jeffrey Hoffmeister, M.D.

Jeffrey Hoffmeister, M.D.

Feature | Breast Imaging | July 05, 2018 | By Jeffrey Hoffmeister, M.D.
When women reach age 40, an annual mammogram becomes a necessary part of their healthcare ritual — regardless if they...
Northern Centre for Cancer Care (NCCC)

Northern Centre for Cancer Care (NCCC).

Sponsored Content | Case Study | Radiation Therapy | July 05, 2018
Established in 2009, Northern Centre for Cancer Care (NCCC) is the largest center of its kind in the north of England....
Overlay Init